Dose-and volume dependent-response to intramuscular injection of botulinum neurotoxin-A optimizes muscle force decrement in mice

Journal of Orthopaedic Research

Volumn 29, Issue 11, 2011, Pages 1764-1770

  Stone, Austin V ^a   Ma, Jianjun ^a   Callahan, Michael F ^a   Smith, Beth P ^a   Garrett, Jeffrey P ^a   Smith, Thomas L ^a   Koman, L Andrew ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

botulinum toxin; dose; mouse; muscle force; volume

Indexed keywords

BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROMYOGRAPHY; GASTROCNEMIUS MUSCLE; MALE; MOUSE; MUSCLE FORCE; MUSCLE MASS; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED STRAINS; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; REACTION TIME;

EID: 80053211045     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21434     Document Type: Article

References (36)

1. Kalandakanond S, Coffield JA,. 2001. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharmacol Exp Ther 296: 980-986. (Pubitemid 32187373)
2. Koman LA, Smith BP, Shilt JS,. 2004. Cerebral palsy. Lancet 363: 1619-1631. (Pubitemid 38625667)
3. Koman LA MJr, Smith B, Goodman A, Mulvaney T,. 1993. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 13: 489-495. (Pubitemid 23174659)
4. Koman LA, Mooney JF III, Smith BP, et al. 2000. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 20: 108-115. (Pubitemid 30013408)
5. Ma J, Shen J, Smith BP, et al. 2007. Bioprotection of tendon repair: adjunctive use of botulinum toxin A in achilles tendon repair in the rat. J Bone Joint Surg Am 89: 2241-2249. (Pubitemid 47606172)
6. Lim ECH, Seet RCS,. 2008. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol Scand 117: 73-84.
7. Kinnett DMD,. 2004. Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil Spasticity Manage Concepts Appl Prospects 83: S59-S64.
8. Koman LA, Paterson Smith B, Balkrishnan R,. 2003. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Pediatr Drugs 5: 11-23. (Pubitemid 36127021)
9. Lowe K, Novak I, Cusick A,. 2006. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 48: 170-175. (Pubitemid 44404261)
10. Aoki KR, Guyer B,. 2001. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8: 21-29. (Pubitemid 33757688)
11. Dimitrova D, Shall M, Goldberg S,. 2002. Short-term effects of botulinum toxin on the lateral rectus muscle of the cat. Exp Brain Res 147: 449-455. (Pubitemid 35440497)
12. Ma J, Elsaidi GA, Smith TL, et al. 2004. Time course of recovery of juvenile skeletal muscle after botulinum toxin a injection: an animal model study. Am J Phys Med Rehabil 83: 774-780.
13. Shen J, Ma J, Elsaidi GA, et al. 2005. Gene expression of myogenic regulatory factors following intramuscular injection of botulinum A toxin in juvenile rats. Neurosci Lett 381: 207-210. (Pubitemid 40719158)
14. Chen C-M, Stott NS, Smith HK,. 2002. Effects of botulinum toxin A injection and exercise on the growth of juvenile rat gastrocnemius muscle. J Appl Physiol 93: 1437-1447.
15. Pamphlett R,. 1989. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92: 181-192. (Pubitemid 19241803)
16. Putten MJAMV, Padberg M, Tavy DLJ,. 2002. In vivo analysis of end-plate noise of human extensor digitorum brevis muscle after intramuscularly injected botulinum toxin type A. Muscle Nerve 26: 784-790. (Pubitemid 35424428)
17. Ugalde I, Christiansen SP, McLoon LK,. 2005. Botulinum toxin treatment of extraocular muscles in rabbits results in increased myofiber remodeling. Invest Ophthalmol Vis Sci 46: 4114-4120. (Pubitemid 44264612)
18. Billante CR, Zealear DL, Billante M, et al. 2002. Comparison of neuromuscular blockade and recovery with botulinum toxins A and F. Muscle Nerve 26: 395-403. (Pubitemid 34977019)
19. Stone AV, Ma J, Whitlock PW, et al. 2007. Effects of Botox® and Neuronox® on muscle force generation in mice. J Orthop Res 25: 1658-1664. (Pubitemid 350293814)
20. Kim HS, Hwang JH, Jeong ST, et al. 2003. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 45: 200-206. (Pubitemid 36221398)
21. Shaari CM, Sanders I,. 1993. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 16: 964-969. (Pubitemid 23246323)
22. Francisco GEMD, Boake CP, Vaughn AOTR,. 2002. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 81: 355-363. (Pubitemid 34412072)
23. Lee L-RMD, Chuang Y-CMDMS, Yang B-JMD, et al. 2004. Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil 83: 766-773. (Pubitemid 40006667)
24. Borodic GE, Ferrante R, Pearce LB, et al. 1994. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 9: 31-39. (Pubitemid 24022612)
25. Flynn TC, Clark RE II., 2003. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29: 519-522, discussion 22. (Pubitemid 36583151)
26. Hsu TSJ, Dover JS, Arndt KA,. 2004. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140: 1351-1354. (Pubitemid 39473635)
27. Shaari CM, George E, Wu BL, et al. 1991. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101: 960-964.
28. Buffelli M, Pasino E, Cangiano A,. 1997. Paralysis of rat skeletal muscle equally affects contractile properties as does permanent denervation. J Muscle Res Cell Motil 18: 683-695. (Pubitemid 27519517)
29. Dodd SL, Selsby J, Payne A, et al. 2005. Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 46: 196-203. (Pubitemid 40966048)
30. Wagatsuma A, Tamaki H, Ogita F,. 2005. Capillary supply and gene expression of angiogenesis-related factors in murine skeletal muscle following denervation. Exp Physiol 90: 403-409. (Pubitemid 40685854)
31. Borisov AB, Huang SK, Carlson BM,. 2000. Remodeling of the vascular bed and progressive loss of capillaries in denervated skeletal muscle. Anat Rec 258: 292-304. (Pubitemid 30146012)
32. Ma J, Smith BP, Smith TL, et al. 2002. Juvenile and adult rat neuromuscular junctions: density, distribution, and morphology. Muscle Nerve 26: 804-809. (Pubitemid 35424431)
33. Atassi MZ,. 2004. Basic immunological aspects of botulinum toxin therapy. Mov Disorder 19: S68-S84. (Pubitemid 38967515)
34. Christopher MS, Elaina G, Bei-Lian W, et al. 1991. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101: 960-964.
35. Ma J, Shen J, Lee CA, et al. 2005. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats. J Orthop Res 23: 302-309. (Pubitemid 40287853)
36. Galatz LM, Charlton N, Das R, et al. 2009. Complete removal of load is detrimental to rotator cuff healing. J Shoulder Elbow Surg 18: 669-675.